INSEAD Day 4 - 728x90

2PointZero posts profit surge

Growth driven by merger consolidation.

Mashreq Q1 profit rises

Total revenue increased 10% year-on-year.

TECOM profit climbs

High occupancy across assets boosts earnings.

Emirates Stallions Q1 revenue up 11%

The rise helped by strong demand in real estate

ADNOC Distribution 2025 dividend $700m

The company had reported EBITDA of $1.17 bn in 2025.

NYU Abu Dhabi team develops wireless pill to control gut neurons

The capsule works without a battery, receiving power wirelessly through magnetic induction from an external transmitter. (NYUAD)
  • The technology was created by Khalil Ramadi, Assistant Professor of Bioengineering at NYU Abu Dhabi and NYU Tandon, and his team.
  • The capsule works without a battery, receiving power wirelessly through magnetic induction from an external transmitter.

Abu Dhabi, UAE — Researchers at NYU Abu Dhabi (NYUAD) have developed an ingestible device that uses light to activate neurons in the gut.

This new technology, called ICOPS (Ingestible Controlled Optogenetic Stimulation), provides a non-invasive way to study and potentially treat digestive and metabolic disorders.

Unlike current methods that require invasive surgery to implant optical fibers, this capsule can be swallowed by patients, offering a significant advantage.

Led by Assistant Professor of Bioengineering Khalil Ramadi, the team’s research, published in Advanced Materials Technologies, demonstrates how ICOPS can wirelessly map and control the intestinal nervous system.

The battery-free capsule is powered by an external transmitter via magnetic induction. According to Mohamed Elsherif, a postdoctoral associate and lead author, the device was entirely fabricated in-house using 3D printing and can operate wirelessly in freely moving animals, enabling studies that were not previously possible.

The researchers believe that beyond its use in research, ICOPS has the potential to enable new treatments for a range of conditions, including gut motility disorders, metabolic diseases, and eating disorders.

Future versions of the capsule could also include electrical stimulation and targeted drug delivery. This innovation could pave the way for a new era of non-invasive medical diagnostics and treatments.